Company: SHPH
Filing Date: 2025-02-26
Form Type: 10-K
Source: 0001493152-25-008300
Chunk: 611

Company: Shuttle Pharmaceuticals Holdings, Inc.
Filing Date: 2025-02-26
Form: 10-K
Item: Item 2
Chunk 611
---
  
     1,046,854 
  
    Legal and professional 
     2,684,665  
     1,328,435 
  
    Total operating expenses 
     7,696,170  
     5,892,382 

    Net loss from operations 
     (7,696,170) 
     (5,892,382)

    Other income (expense) 

    Interest expense - related parties 
     (8,692) 
     (6,825)
  
    Interest expense 
     (1,198,738) 
     (2,484,193)
  
    Interest income 
     38,138  
     79,117 
  
    Convertible notes finance fee 
     (152,726) 
     (104,245)
  
    Change in fair value of derivative liabilities 
     555,789  
     2,216,488 
  
    Change in fair value of convertible notes 
     122,553  
     — 
  
    Gain on sale of marketable securities 
     28,550  
     4,970 
  
    Change in fair value of marketable securities 
     — 
     71,568 
  
    Loss on settlement of convertible debt 
     (833,501) 
     (477,221)
  
    Total other income (expense) 
     (1,448,627) 
     (700,341)

    Net loss 
     (9,144,797) 
     (6,592,723)

    Weighted average common shares outstanding - basic 
     2,870,120  
     1,866,275 
  
    Net loss per shares - basic 
    $(3.19) 
    $(3.53)
  
    Weighted average common shares outstanding - diluted 
     2,887,268  
    $1,866,275 
  
    Net loss per shares - diluted 
    $(3.30) 
    $(3.53)

The
accompanying notes are an integral part of these consolidated financial statements.

F-3

Shuttle
Pharmaceuticals Holdings, Inc.

Consolidated
Statements of Changes in Stockholders’ Equity

For
the Years Ended December 31, 2024 and 2023

    Shares  
    Amount  
    Capital